Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

EUR60.9 million on September 30, 2008 and EUR58.9 million on December 31, 2008. Business Highlights Clinical Highlights

Microplasmin - Back of the Eye Disease: Phase III clinical program to evaluate non-surgical treatment of patients with vitreomacular adhesion.

- Phase III program continues to progress well, with enrolment

completed for TG-MV 006 and on track for TG-MV 007

In September, ThromboGenics announced the completion of patient recruitment in the US trial (TG-MV-006) of the Phase III program with microplasmin for the non-surgical treatment of vitreomacular adhesion (a back of the eye condition). The trial recruited a total of 326 patients ahead of schedule and we anticipate reporting the results from this study by mid 2010, after a 6 month follow up period.

The second Phase III study with microplasmin, TG-MV-007, which is recruiting 320 patients in Europe and the US, is progressing well and we expect complete enrolment within the first quarter of 2010 and results of this study near the end of 2010.

This Phase III program, referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program, comprises two clinical trials, taking place in the United States (TG-MV-006 trial) and a second combined European and US study (TG-MV-007 trial). The indication for both of these Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion. Vitreomacular adhesion is a condition in which the vitreous has an abnormally strong adhesion to the retina at the back of the eye. These adhesions can cause vessel and retinal distortion, which results in deterioration in the patient's vision. Both of these trials use the 125micro g dose of microplasmin.

Microplasmin - Diabetic Retinopathy: Phase II trial to evaluate microplasmin for the treatment of Diabetic Macular E
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...TY,Calif.,Nov.24/PRNewswire-FirstCall/--GenomicHea...t,GenomicHealth,sExecutiveChairman,willpresentatth...rkCityonTuesday,December1,2009at10:00a.m.ET. ,,...epresentation,visittheInvestorRelationssectionofGe...th.com .Pleaseconnecttothewebsiteatleast15minutesp...
(Date:11/24/2009)... Chemical Abstracts Service (CAS), the glo...hina,s patent office is now the world,s leading pr...ry. China trailed Japan,s patent office, the World...e United States Patent and Trademark Office (USPTO...2005, WIPO in 2006, and exceeded Japan for the fir...
(Date:11/23/2009)... You can think of it as origami very high-tech o...is have developed a technique for fabricating thre...es from thin films by coupling photolithography an...actions. , The films, only a few microns thick, o...ith thicker pieces of the same material. , "This ...
(Date:11/23/2009)...LLAGE,Nev.,Nov.23/PRNewswire-FirstCall/--PDLBioPha...AQhasestablishedNovember27,2009astheex-dividenddat...ultingfromthesecuritizationtransactioncompletedonN...09toallstockholdersofrecordontherecorddate,Decembe...thedividendat$1.67pershareofcommonstockforpurposes...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Water droplets direct self-assembly process in thin-film materials 2PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2
...wswire-Asia-FirstCall/ -- China,Biologic Products,... or the,"Company"), one of the leading plasma-base...c of China ("PRC"), today announced that one of it...ill be listed in the National Torch,Plan of China....xecuted in 1988, by China,s,Ministry of Science an...
...ire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, In...Company"),a leading manufacturer and distributor o...cts in China, today reported financial results for...31, 2008. , "Sales of our glucose products inc... September quarter," said Mr. Qingtai Liu, Shengta...
...ogies announces the launch of its new informative ...interactive e-book designed to introduce the gener...ying biotechnologies behind the clinical developme...ly targeted, genetic medicine that has been valida...Genetics, 2007), Rexin-G is designed to seek-out a...
Other Biology Technology:China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 2China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 3Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 2Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 3Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 4Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 5Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 6Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 7Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 8Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 9Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 10Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 11Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial 2
(Date:11/23/2009)...research presents strong evidence that the "synerg...or traffic-related pollution and indoor endotoxin ...he other exposure alone. , Environmental healt...College of Medicine have shown that children expos...s and indoor endotoxin during early life are six t...
(Date:11/23/2009)...ember 23, 2009 - The time of day matters to forest...per produced by a research team led by Professor M...,s vice-principal for research and colleagues in t...t. George campus. , Capitalizing on their prev... the research team examined how poplar trees use t...
(Date:11/23/2009)... Current research suggests that a common oral bac...ated report by Nichols et al, "Unique Lipids from ...TLR2 Ligands Capable of Enhancing Autoimmunity," a... Journal of Pathology . , Multiple sclerosis (MS...rain and spinal cord, affects nearly 1 in 700 peop...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Factors from common human bacteria may trigger multiple sclerosis 2All Fifty States to Screen Newborns for Cystic Fibrosis by 2010 50906 1All Fifty States to Screen Newborns for Cystic Fibrosis by 2010 50906 2Whole Foods Market 28R 29 Partners With Non GMO Project to Label Companys Private Label Food Products Using New Third Party Standard 50904 1Whole Foods Market 28R 29 Partners With Non GMO Project to Label Companys Private Label Food Products Using New Third Party Standard 50904 2Whole Foods Market 28R 29 Partners With Non GMO Project to Label Companys Private Label Food Products Using New Third Party Standard 50904 3Whole Foods Market 28R 29 Partners With Non GMO Project to Label Companys Private Label Food Products Using New Third Party Standard 50904 4Jazz Pharmaceuticals Completes 247 Million Private Placement 50902 1Jazz Pharmaceuticals Completes 247 Million Private Placement 50902 2
...aren Beemon has been awarded the third annual Retr...eque and a crystal trophy and is interviewed in an...l Retrovirology. She is Professor and Chair of the... I am very honored to receive the 2007 Retrovirolo...e Retrovirology community. It is gratifying that t...
...selaer Polytechnic Institute have developed a new ...rous proteins such as anthrax toxin, and render th... lends itself to the creation of new antibacterial...f germs, and also holds promise for new methods of... , Scientists have long been interested in wrappi...
...rons is a hallmark of many neurodegenerative disea...ell biology and regenerative medicine offer novel ... This week in the online open-access journal PLoS ...jeshwar Awatramani, and Dr. Ronald McKay show that...le in the birth and death of dopamine neurons in t...
Other Biology News:Karen Beemon wins the 2007 Retrovirology Prize 2Using carbon nanotubes to seek and destroy anthrax toxin and other harmful proteins 2
Rabbit Anti-NMDA NR2B, phospho (Tyr1336) Polyclonal Antibody, Unconjugated from Novus Biologicals
MTT Reagent A from CHEMICON
Mouse Anti-Human ALS2CR8 Polyclonal Antibody, Unconjugated from Novus Biologicals
PIP Strips from Echelon Biosciences Inc.
Biology Products: